UNIGE document Scientific Article
previous document  unige:90881  next document
add to browser collection
Title

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

Authors
Hottinger, A F
Aissa, A B
Espeli, V
Squiban, D
Hundsberger, T
show hidden authors show all authors [1 - 12]
Published in British Journal of Cancer. 2014, vol. 110, no. 11, p. 2655-2661
Abstract Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma.
Keywords AdultAgedAntineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicityBrain Neoplasms/mortality/therapyChemoradiotherapyDacarbazine/administration & dosage/analogs & derivativesDisease-Free SurvivalFemaleGlioblastoma/mortality/therapyHumansMaleMaximum Tolerated DoseMiddle AgedNiacinamide/administration & dosage/analogs & derivativesPhenylurea Compounds/administration & dosageTreatment Outcome
Identifiers
PMID: 24786603
Full text
Article (Published version) (462 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research groups Groupe Schaller Karl Lothard (neurochirurgie) (851)
Traits génétiques complexes (901)
Immunothérapie des cancers (42)
Citation
(ISO format)
HOTTINGER, A F et al. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. In: British Journal of Cancer, 2014, vol. 110, n° 11, p. 2655-2661. https://archive-ouverte.unige.ch/unige:90881

50 hits

0 download

Update

Deposited on : 2017-01-06

Export document
Format :
Citation style :